SDK002 (arsenic trioxide)

SDK002 is an orally administered formulation of arsenic trioxide (ATO) currently under clinical investigation for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). While arsenic trioxide is traditionally administered intravenously for acute promyelocytic leukemia, SDK002 is being evaluated as part of a novel combination regimen including all-trans retinoic acid (ATRA), the immune checkpoint inhibitor tislelizumab, and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel). The mechanism of action involves the induction of apoptosis, generation of reactive oxygen species (ROS), and inhibition of the Hedgehog signaling pathway by targeting GLI transcription factors. This oral formulation aims to improve patient convenience and potentially alter the pharmacokinetic profile to enhance efficacy in solid tumors by modulating the tumor microenvironment and sensitizing cancer cells to immunotherapy.

Other names

arsenic trioxideATO